4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel SyndromeNew data demonstrating clinical activity in both IBS-C and IBS-D was presented at Digestive Disease Week 2021Company to host webcast on Tuesday, May 25, 2021 at 12:00 p.m. EDLeeds, UK, May 24.